2018 Alcoholic Hepatitis Drug Development- Pipeline Analysis Report
Long term heavy intake of alcohol results in Alcoholic Hepatitis, a stage in Hepatitis liver disease. It is associated with fatty liver, fibrosis and can also lead to cirrhosis. Typically, the patients are administered with corticosteroids.
Around 20 companies and universities are focusing on developing treatment options for Alcoholic Hepatitis.
To assist researchers and business development managers, VPA Research has come up with a comprehensive report on Alcoholic Hepatitis pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Alcoholic Hepatitis pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Alcoholic Hepatitis pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
Around 20 companies and universities are focusing on developing treatment options for Alcoholic Hepatitis.
To assist researchers and business development managers, VPA Research has come up with a comprehensive report on Alcoholic Hepatitis pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Alcoholic Hepatitis pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Alcoholic Hepatitis pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
1 TABLE OF CONTENTS
1.1 List of Figures
1.2 List of Tables
2 ALCOHOLIC HEPATITIS PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Alcoholic Hepatitis Pipeline Snapshot
2.3 Alcoholic Hepatitis Pipeline by Phase
2.4 Alcoholic Hepatitis Pipeline by Company
2.5 Alcoholic Hepatitis Pipeline by Mechanism of Action
3 ALCOHOLIC HEPATITIS- COMPANY WISE PIPELINE ANALYSIS
Afimmune
DS Biopharma
DURECT Corporation
Generon Corporation (Shanghai) Ltd.
Gilead Sciences
GRI Bio
Hadasit Medical Research Services & Development Ltd
Immuron
Intercept Pharmaceuticals
PharmaKing
Promethera Biosciences
Sumitomo Dainippon Pharma Co Ltd
Vectus Biosystems Ltd
Verlyx
Vital Therapies
4 ALCOHOLIC HEPATITIS R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN ALCOHOLIC HEPATITIS PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
1.1 List of Figures
1.2 List of Tables
2 ALCOHOLIC HEPATITIS PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Alcoholic Hepatitis Pipeline Snapshot
2.3 Alcoholic Hepatitis Pipeline by Phase
2.4 Alcoholic Hepatitis Pipeline by Company
2.5 Alcoholic Hepatitis Pipeline by Mechanism of Action
3 ALCOHOLIC HEPATITIS- COMPANY WISE PIPELINE ANALYSIS
Afimmune
DS Biopharma
DURECT Corporation
Generon Corporation (Shanghai) Ltd.
Gilead Sciences
GRI Bio
Hadasit Medical Research Services & Development Ltd
Immuron
Intercept Pharmaceuticals
PharmaKing
Promethera Biosciences
Sumitomo Dainippon Pharma Co Ltd
Vectus Biosystems Ltd
Verlyx
Vital Therapies
4 ALCOHOLIC HEPATITIS R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN ALCOHOLIC HEPATITIS PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
LIST OF FIGURES
Figure 1: Alcoholic Hepatitis Pipeline by Phase, H1- 2018
Figure 2: Alcoholic Hepatitis Pipeline by Companies, H1- 2018
Figure 3: Company Wise Pipeline Drug Phases, H1- 2018
Figure 4: Alcoholic Hepatitis Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018
Figure 1: Alcoholic Hepatitis Pipeline by Phase, H1- 2018
Figure 2: Alcoholic Hepatitis Pipeline by Companies, H1- 2018
Figure 3: Company Wise Pipeline Drug Phases, H1- 2018
Figure 4: Alcoholic Hepatitis Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018
LIST OF TABLES
Table 1: Alcoholic Hepatitis Pipeline by Phase, H1- 2018
Table 2: Alcoholic Hepatitis Pipeline by Companies, H1- 2018
Table 3: Alcoholic Hepatitis Pipeline by Mechanism of Action, H1- 2018
Table 4: Afimmune Alcoholic Hepatitis Pipeline, May 2018
Table 5: DS Biopharma Alcoholic Hepatitis Pipeline, May 2018
Table 6: DURECT Corporation Alcoholic Hepatitis Pipeline, May 2018
Table 7: Generon Corporation (Shanghai) Ltd. Alcoholic Hepatitis Pipeline, May 2018
Table 8: Gilead Sciences Alcoholic Hepatitis Pipeline, May 2018
Table 9: GRI Bio Alcoholic Hepatitis Pipeline, May 2018
Table 10: Hadasit Medical Research Services & Development Ltd Alcoholic Hepatitis Pipeline, May 2018
Table 11: Immuron Alcoholic Hepatitis Pipeline, May 2018
Table 12: Intercept Pharmaceuticals Alcoholic Hepatitis Pipeline, May 2018
Table 13: PharmaKing Alcoholic Hepatitis Pipeline, May 2018
Table 14: Promethera Biosciences Alcoholic Hepatitis Pipeline, May 2018
Table 15: Sumitomo Dainippon Pharma Co Ltd Alcoholic Hepatitis Pipeline, May 2018
Table 16: Vectus Biosystems Ltd Alcoholic Hepatitis Pipeline, May 2018
Table 17: Verlyx Alcoholic Hepatitis Pipeline, May 2018
Table 18: Vital Therapies Alcoholic Hepatitis Pipeline, May 2018
Table 1: Alcoholic Hepatitis Pipeline by Phase, H1- 2018
Table 2: Alcoholic Hepatitis Pipeline by Companies, H1- 2018
Table 3: Alcoholic Hepatitis Pipeline by Mechanism of Action, H1- 2018
Table 4: Afimmune Alcoholic Hepatitis Pipeline, May 2018
Table 5: DS Biopharma Alcoholic Hepatitis Pipeline, May 2018
Table 6: DURECT Corporation Alcoholic Hepatitis Pipeline, May 2018
Table 7: Generon Corporation (Shanghai) Ltd. Alcoholic Hepatitis Pipeline, May 2018
Table 8: Gilead Sciences Alcoholic Hepatitis Pipeline, May 2018
Table 9: GRI Bio Alcoholic Hepatitis Pipeline, May 2018
Table 10: Hadasit Medical Research Services & Development Ltd Alcoholic Hepatitis Pipeline, May 2018
Table 11: Immuron Alcoholic Hepatitis Pipeline, May 2018
Table 12: Intercept Pharmaceuticals Alcoholic Hepatitis Pipeline, May 2018
Table 13: PharmaKing Alcoholic Hepatitis Pipeline, May 2018
Table 14: Promethera Biosciences Alcoholic Hepatitis Pipeline, May 2018
Table 15: Sumitomo Dainippon Pharma Co Ltd Alcoholic Hepatitis Pipeline, May 2018
Table 16: Vectus Biosystems Ltd Alcoholic Hepatitis Pipeline, May 2018
Table 17: Verlyx Alcoholic Hepatitis Pipeline, May 2018
Table 18: Vital Therapies Alcoholic Hepatitis Pipeline, May 2018
